UBS Group
JANX icon

UBS Group’s Janux Therapeutics JANX Stock Holding History

UBS Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.31M Sell
150,701
-69,105
-31% -$1M ﹤0.01% 4989
2026
Q1 		$3.06M Sell
219,806
-370,254
-63% -$5.08M ﹤0.01% 4582
2025
Q4 		$8.14M Buy
590,060
+199,703
+51% +$4.7M ﹤0.01% 3512
2025
Q3 		$9.54M Buy
390,357
+97,824
+33% +$2.38M ﹤0.01% 3341
2025
Q2 		$6.76M Sell
292,533
-195,947
-40% -$5.16M ﹤0.01% 3550
2025
Q1 		$13.2M Buy
488,480
+263,390
+117% +$9.93M ﹤0.01% 2769
2024
Q4 		$12.1M Buy
225,090
+170,896
+315% +$9.04M ﹤0.01% 2851
2024
Q3 		$2.46M Buy
54,194
+3,326
+7% +$145K ﹤0.01% 3796
2024
Q2 		$2.13M Buy
50,868
+28,664
+129% +$1.35M ﹤0.01% 3716
2024
Q1 		$836K Buy
+22,204
New +$484K ﹤0.01% 4744
2023
Q2 		– Sell
-841
Closed -$10.2K – 9264
2023
Q1 		$10.2K Buy
841
+628
+295% +$10.5K ﹤0.01% 7601
2022
Q4 		$2.81K Buy
+213
New +$3.12K ﹤0.01% 9622
2022
Q2 		– Sell
-3,500
Closed -$50K – 10625
2022
Q1 		$50K Sell
3,500
-185
-5% -$3.03K ﹤0.01% 6497
2021
Q4 		$73K Buy
3,685
+185
+5% +$3.88K ﹤0.01% 6574
2021
Q3 		$76K Buy
3,500
+3,147
+892% +$90.5K ﹤0.01% 6025
2021
Q2 		$9K Buy
+353
New +$7.86K ﹤0.01% 8142

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

UBS Group's JANX Position: Q2 2026 in Review

UBS Group reduced its Janux Therapeutics (JANX) stake by 31% in Q2 2026, selling an estimated $1M and leaving 150,701 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #4989.

UBS Group first reported a position in JANX in Q2 2021 and has held it in 16 quarters since. The position peaked at $13.2M in Q1 2025. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • UBS Group held 150,701 shares of Janux Therapeutics worth $2.31M as of Q2 2026.
  • UBS Group sold 69,105 Janux Therapeutics shares in Q2 2026, an estimated $1M.
  • Janux Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4989 holding.
  • UBS Group first reported a position in Janux Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • UBS Group's Janux Therapeutics position peaked at $13.2M in Q1 2025.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.